Pyxis Oncology

NSQ:PYXS · US7473241013

BiotechnologySmall

360

Medium confidence — indicative

Value—

Profit price—

Cash yield—

Sales & asset price43

Price/Sales1

EV / Gross Profit50

Price/Book78

Quality48

Returns on capital27

Return on Capital30

Return on Equity24

Profit margins71

Cash truth not applicable for financial companies.

Growth44

Sales growth16

Profit growth52

Reinvestment57

Price momentum42

Safety57

Debt load17

Debt serviceability15

Liquidity95

Sentiment49

Analyst ratings45

Expectations trend88

Market mood49

Value Creation10/20creating some value

Creates more value than its capital costs
Owner earnings growing
Owner earnings per share growing
Reinvests at strong returns
Solid earnings base

What this means

Pyxis Oncology clears its cost of capital, but the record is mixed across the five tests. Real value creation, just not yet consistent.

Based on 3/5 components.

Profile

CountryUSA

IndustryBiotechnology

SizeSmall

TypePublic Company

ExchangeNASDAQGS

Founded2018

Employees65

Websitepyxisoncology.com

ISINUS7473241013

Last UpdateApr 2, 2026

Indices

NASDAQ (USA)

Themes

ImmunologyOphthalmologyOncologyHematologyBiotechnologyHealth CarePharmaceutical

Description

Pyxis Oncology, Inc. (Pyxis Oncology) operates as a clinical-stage oncology company advancing a development strategy focused on addressing unmet medical needs in patients with solid tumors with an immediate focus on head and neck squamous cell carcin…

Analysis

Middle-of-the-road

Pyxis Oncology, Inc. is a middle-of-the-road business: neither the economics nor the price stand out from the peer group.

Valuation data is not available for this company.

The trajectory is moderate and the balance sheet is adequate. The company scores 10/20 on our value-creation score: creating some value.

Nothing is flagged here: no red or amber gates, no divergence between profits and cash. That is itself information: the numbers are straightforward. As always: this describes the company's numbers; it is not a recommendation.

360° rank · history

1007550250

2026

All-time high

Jun 2026

All-time low

Mar 2026

Average rank

across all years

Detailed & Historical Ranks

Deep dive into 15 detailed ranks and 3 years of history.

Current202520242023

Price/Sales

—

Price/Earnings

—

Price/Book

—

Dividend Yield

—

Value (overall)

—

Cells are coloured by rank band (red weak → green strong). Sentiment & 360° history begins 2023.

Similar Stocks

The companies this stock is ranked against.

Compare Pyxis Oncology with its peers

Tango Therapeutics

NMQ:TNGX

CountryUSA

IndustryBiotechnology

SizeSmall

Full Stock Analysis →

Spyre Therapeutics

NSQ:SYRE

—

CountryUSA

IndustryBiotechnology

SizeSmall

Full Stock Analysis →

Zura Bio

NAQ:ZURA

CountryUSA

IndustryBiotechnology

SizeSmall

Full Stock Analysis →

Aura Biosciences

NMQ:AURA

—

CountryUSA

IndustryBiotechnology

SizeSmall

Full Stock Analysis →

ImageneBio

NAQ:IMA

CountryUSA

IndustryPharmaceuticals

SizeSmall

Full Stock Analysis →

MacroGenics

NSQ:MGNX

CountryUSA

IndustryBiotechnology

SizeSmall

Full Stock Analysis →

Make Sense of the Ranks

Every rank runs 1–100 against true peers. Higher is always better.

360° View

1 · Watch OutGood· 100

Value

1 · ExpensiveGood Value· 100

Quality

1 · Weak FundamentalsHigh Quality· 100

Growth

1 · Tough TimesHigh Growth· 100

Safety

1 · High LeverageWell-Financed· 100

Sentiment

1 · SkepticismPositive· 100

Learn More →